TruScreen Group (ASX:TRU, NZE:TRU) has re-entered the Indian market with the appointment of Renovate Biologicals as distributor of its artificial intelligence-enabled cervical cancer screening product, according to a Wednesday New Zealand and Australian bourse filing.
The company said its technology is non-invasive and may be preferred by certain subgroups as it does not require a collection of cervical cells, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.